Assertio Holdings, Inc. (ASRT)
Jun 16, 2026 - ASRT was delisted (reason: merged with Zydus Lifesciences)
23.50
+0.02 (0.09%)
Inactive · Last trade price on Jun 15, 2026

Assertio Holdings Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
102.16118.71124.96152.07156.23111.01
Revenue Growth
-14.15%-5.00%-17.83%-2.67%40.73%2.72%
Gross Profit
71.8583.3385.73125.05137.4995.78
Operating Income
-22.75-17.22-18.7824.9456.7721.18
Net Income
-35.69-30.38-21.58-331.94109.63-1.28
Earnings Per Share
-5.56-4.74-3.40-70.1030.51-0.45
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
71.5763.41100.0573.4464.9436.81
Total Debt
40.3140.2540.2740.9167.2775.87
Net Cash (Debt)
31.2623.1559.7932.53-2.33-39.06
Net Cash Growth
-33.55%-61.28%83.80%---
Net Cash Per Share
4.873.629.416.87-0.64-13.57

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-7.08-28.1826.4149.678.65.52
Capital Expenditures
----0.63-0.27-0.05
Free Cash Flow
-7.08-28.1826.4148.9878.325.47
Free Cash Flow Growth
---46.08%-37.47%1331.88%-

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
70.33%70.19%68.61%82.23%88.00%86.28%
Operating Margin
-22.27%-14.51%-15.03%16.40%36.34%19.08%
Pretax Margin
-34.71%-25.22%-17.23%-167.06%19.95%-0.50%
Profit Margin
-34.94%-25.59%-17.27%-218.28%70.17%-1.15%
FCF Margin
-6.93%-23.74%21.13%32.21%50.13%4.93%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----1.89-
Forward PE
19.26--53.508.2611.47
P/FCF Ratio
--3.152.072.6517.79
PS Ratio
1.490.490.670.671.330.88